INSIGHTS Study: Investigational Drug Treatment for Patients with Advanced Parkinson's Disease

Clinical Trial Title

INSIGHTS study: An open-label, randomized 26-week study comparing levodopa-carbidopa INteStInal gel (LCIG) THerapy to optimized medical treatment (OMT) on non-motor symptoms (NMS) in subjects with advanced Parkinson's disease.

Contact Information

Leonardo Verhagen Metman, MD, PhD

Clinical Trial Protocol Description:

The purpose of this study is to find out how well the investigational drug known as levodopa carbidopa intestinal gel (LCIG) and its delivery system (through infusion) work to treat nonmotor symptoms (insomnia [inability to sleep], depression, anxiety) in patients with advanced Parkinson's disease compared to optimized medical treatment.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have Parkinson’s disease with non-motor symptoms.
  • Are 30 years of age or older.
  • Have Parkinson’s disease responsive to levodopa.

You will be excluded from the study if any of the following criteria apply to you:

  • Have an unclear diagnosis of Parkinson’s disease (secondary parkinsonism).
  • Have undergone neurosurgery for treatment of Parkinson’s disease.
  • Have hypersensitivity to levodopa, carbidopa or radiopaque material.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Leonardo Verhagen Metman, MD, PhD

Contact Information

Leonardo Verhagen Metman, MD, PhD

(312) 563-2900
Press 4
Code name: M12-927


Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more